Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06045507 · ClinicalTrials.gov registry record · Phase 2
Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)
A Phase 2 study of HIV and HIV Pre-exposure Prophylaxis, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 352
- Enrollment target
- 18
- Study locations
NCT06045507 is a Phase 2 study of HIV and HIV Pre-exposure Prophylaxis that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 352 participants, below the 439-participant average among 303 other HIV trials with a reported enrollment target (20% lower). The trial reports 18 study locations across 13 states.
The verdict
NCT06045507, a Phase 2 study of HIV and HIV Pre-exposure Prophylaxis, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 352 participants
- Enrollment target
- 18
- Study locations
Study Summary
This double-blind, placebo-controlled study was designed to assess the safety, tolerability, and pharmacokinetics of oral MK-8527 taken once monthly (QM) in participants at low risk for human immunodeficiency virus Type 1 (HIV-1) infection.
Conditions Studied
Interventions
- DRUG MK-8527
- DRUG Placebo to MK-8527
Study Locations (18)
Other
- Rambam Health Care Campus ( Site 0003) - Haifa
- Hadassah Medical Center ( Site 0002) - Jerusalem
- Sheba Medical Center ( Site 0001) - Ramat Gan
California
- Velocity Clinical Research, North Hollywood ( Site 0054) - North Hollywood
- Bridge HIV- San Francisco Department of Public Health ( Site 0042) - San Francisco
Florida
- Velocity Clinical Research, Hallandale Beach ( Site 0052) - Hallandale
- Community Medical Care Center ( Site 0056) - Immokalee
Gauteng
- Wits RHI-Wits RHI Ward 21 Clinical Research site ( Site 0027) - Johannesburg
- Helen Joseph Hospital ( Site 0024) - Johannesburg
Maryland
- Velocity Clinical Research Rockville ( Site 0048) - Rockville
Massachusetts
- Fenway Health ( Site 0043) - Boston
New Mexico
- Albuquerque Clinical Trials, Inc. ( Site 0044) - Albuquerque
Pennsylvania
- University of Pittsburgh Medical Center-Division of Infectious Diseases ( Site 0041) - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 352 participants |
| Start Date | 2023-11-08 |
| Est. Completion | 2025-02-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06045507
The ClinicalTrials.gov registry entry for NCT06045507 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 352 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 439-participant average among 303 other HIV trials with a reported enrollment target (20% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV appearing as the primary indexed condition, and to 2 interventions - of which MK-8527 is the first listed.
NCT06045507 reports 18 study locations spanning 13 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06045507 about?
NCT06045507 is a clinical study titled "Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)". This double-blind, placebo-controlled study was designed to assess the safety, tolerability, and pharmacokinetics of oral MK-8527 taken once monthly (QM) in participants at low risk for human immunodeficiency virus Type 1 (HIV-1) infection.
What is the current status of trial NCT06045507?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 352 participants. The study started on 2023-11-08. Estimated completion is 2025-02-12.
What conditions does trial NCT06045507 study?
This clinical trial studies the following conditions: HIV, HIV Pre-exposure Prophylaxis.
What interventions are being tested in trial NCT06045507?
The interventions under investigation include: MK-8527 (DRUG), Placebo to MK-8527 (DRUG).
Who is sponsoring clinical trial NCT06045507?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06045507 being conducted?
This trial has 18 study locations across California, Florida, Maryland, Massachusetts, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
Improving Physical Ability and Cellular Senescence Elimination in HIV
RECRUITING · Phase 2
-
Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV
RECRUITING · Phase 2
-
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide
RECRUITING · Phase 2
-
Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV
RECRUITING · Phase 2
-
A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.